8-K: Spero Therapeutics Q3: Tebipenem HBr Advances, SPR720 Halted

Spero Therapeutics announced third quarter 2025 financial results, highlighted by positive Phase 3 PIVOT-PO trial data for tebipenem HBr, its planned FDA submission by GSK, and the discontinuation of the SPR720 program.

Summary

• Spero Therapeutics reported a net loss of $7.4 million for the third quarter of 2025, a significant improvement from a net loss of $17.1 million for the third quarter of 2024.
• Total revenue for Q3 2025 was $5.4 million, down from $13.5 million in Q3 2024, primarily due to decreased collaboration and grant revenue.
• Research and development expenses decreased to $8.6 million in Q3 2025 from $26.9 million in Q3 2024, mainly due to reduced clinical expenses for the PIVOT-PO Trial and the SPR720 program.
• General and administrative expenses for Q3 2025 were $4.2 million, compared to $5.2 million for the same period in 2024, primarily due to lower personnel-related costs.
• As of September 30, 2025, Spero had cash and cash equivalents of $48.6 million, which is estimated to fund operations into 2028.
• The Phase 3 PIVOT-PO trial for tebipenem HBr in complicated urinary tract infection (cUTI) met its primary endpoint, demonstrating non-inferiority to intravenous imipenem-cilastatin, leading to an early stop for efficacy in May 2025.
• GSK, Spero's development partner, plans to submit data from the PIVOT-PO trial as part of a planned US Food and Drug Administration (FDA) filing in Q4 2025, with an anticipated regulatory decision in 2H 2026.
• The SPR720 program, an investigational antibiotic for nontuberculous mycobacterium pulmonary disease (NTM-PD), was discontinued in Q3 2025 following a review of complete data from Phase 2a and Phase 1 trials.

Sentiment

Score: 7

Explanation: The positive clinical trial results for tebipenem HBr and the extended cash runway are strong positives, despite the revenue decrease and program discontinuation. The planned FDA submission by GSK is a significant step towards commercialization.

Positives

• The Phase 3 PIVOT-PO trial for tebipenem HBr successfully met its primary endpoint, demonstrating non-inferiority to IV imipenem-cilastatin for cUTI, leading to an early stop for efficacy.
• GSK plans to submit tebipenem HBr data to the FDA in Q4 2025, a critical step towards potential market approval.
• Tebipenem HBr is positioned as a potential first-in-class oral carbapenem for cUTI, offering an important alternative to IV therapies and potentially shortening hospital stays.
• Net loss significantly decreased to $7.4 million in Q3 2025 from $17.1 million in Q3 2024, indicating improved financial efficiency.
• Research and development expenses decreased substantially by $18.3 million in Q3 2025 compared to Q3 2024, reflecting cost management.
• The company's cash and cash equivalents of $48.6 million are projected to fund operating expenses and capital expenditures into 2028, providing a healthy cash runway.
• The global collaboration with GSK includes robust financial terms, with eligibility for up to $351 million in additional potential regulatory, commercial, and sales milestone payments, plus tiered sales royalties.

Negatives

• Total revenue decreased to $5.4 million in Q3 2025 from $13.5 million in Q3 2024, primarily due to reduced collaboration revenue with GSK and a decrease in grant revenue.
• The SPR720 program for nontuberculous mycobacterium pulmonary disease (NTM-PD) was discontinued in Q3 2025 after reviewing trial data, representing a setback in the pipeline.
• The maximum potential milestone payment from GSK was revised from $150 million to $95 million after the PIVOT-PO trial was stopped early for efficacy, reducing the overall cost of the study to the Company.

Risks

• Whether the results of any clinical trials will warrant submission for approval from the FDA or equivalent foreign regulatory agencies.
• Whether the FDA will ultimately approve tebipenem HBr and, if so, the timing of any such approval, taking into account the effects of possible regulatory delays.
• Whether the FDA will require any additional clinical data or place labeling restrictions on the use of tebipenem HBr that would delay approval and/or reduce the commercial prospects of tebipenem HBr.
• Whether a successful commercial launch can be achieved and market acceptance of tebipenem HBr can be established.
• Reliance on third parties, particularly GSK, to manufacture, develop, and commercialize product candidates, if approved, and GSK's right to determine, in its sole discretion, whether to further develop tebipenem HBr.
• The company's need for additional funding beyond its current cash resources.
• The company's ability to retain key personnel.
• Whether the company's cash resources will be sufficient to fund its continuing operations for the periods anticipated.
• The lengthy, expensive, and uncertain process of clinical drug development.
• The company's ability to obtain adequate third-party reimbursement for its product candidates.
• Whether the company will satisfy all of the pre-conditions to receipt of the milestone payments under its various license and collaboration agreements.
• The company's ability to implement its strategic plans.
• The company's ability to obtain, maintain, and enforce intellectual property and other proprietary rights for its product candidates.
• Risks and uncertainties related to market conditions.

Future Outlook

GSK plans to submit data from the PIVOT-PO trial for tebipenem HBr to the US FDA in Q4 2025, with an anticipated regulatory decision in the second half of 2026. The company expects its current cash and cash equivalents of $48.6 million to fund operations into 2028.

Management Comments

• "We are pleased to have shared the Phase 3 PIVOT-PO study results for tebipenem HBr with the medical community at this year's IDWeek conference in October."
• "We are working alongside our partner, GSK, to enable them to submit the FDA filing this quarter and we anticipate regulatory decision in 2H 2026."
• "If approved, tebipenem HBr as an oral option could provide an important alternative to IV carbapenem therapies for complicated urinary tract infections, with the potential to shorten hospital stays and improve treatment burden for patients."

Industry Context

The filing positions tebipenem HBr as a potential first-in-class oral carbapenem for complicated urinary tract infections (cUTI), addressing a significant unmet need due to increasing antimicrobial resistance and the current reliance on intravenous therapies. This development could revolutionize cUTI treatment by offering an effective oral option, potentially reducing hospital stays and associated healthcare costs for the estimated 2.9 million annual cUTI treatment episodes in the US. The discontinuation of the SPR720 program highlights the inherent high-risk nature of drug development, particularly in challenging areas like nontuberculous mycobacterium pulmonary disease (NTM-PD), where clinical success is not guaranteed.

Comparison to Industry Standards

• Tebipenem HBr is positioned as the potential first oral carbapenem for cUTI, offering a significant advantage over existing IV carbapenem therapies like imipenem-cilastatin by enabling outpatient treatment.
• Compared to other oral candidates for cUTI, such as Basilea's Ceftibuten-ledaborbactam etzadroxil (Phase 1) and Shionogi/Qpex's Ceftibuten-xeruborbactam oral prodrug (Phase 1), tebipenem HBr is significantly more advanced, having completed Phase 3 trials and moving towards FDA submission.
• For uncomplicated UTIs, commercial options like Iterum's Sulopenem etzadroxil and probenecid (Orlynvah), Pivmecillinam (Pivya, NDA Approved Apr 2024), and GSK's Gepotidacin (NDA Approved March 2025) exist, but tebipenem HBr targets the more severe and complex cUTI market.
• The active drug, Tebipenem Pivoxil, has a proven track record in Japan since 2009 for pediatric pneumonia, otitis media, and sinusitis, with over 4 million patients dosed, suggesting a well-established safety and efficacy profile in other indications.

Stakeholder Impact

• Shareholders: Potential for increased value if tebipenem HBr is approved and commercialized, but also risks associated with drug development and reliance on GSK. Reduced net loss and extended cash runway are positive for financial stability.
• Patients (cUTI): Potential for a new, effective oral treatment option, which could shorten hospital stays and improve treatment burden.
• Employees: Discontinuation of SPR720 program might impact employees involved in that specific project.
• GSK: Progress towards FDA submission for a licensed product.

Next Steps

• GSK to submit data from the PIVOT-PO trial as part of a planned US FDA filing in Q4 2025.
• Anticipated regulatory decision for tebipenem HBr in 2H 2026.
• Determine next steps for the SPR720 program after completing data analysis (though the program has been suspended).

Key Dates

Recommendation

The successful Phase 3 trial for tebipenem HBr and the upcoming FDA submission by GSK are significant positive catalysts, potentially leading to the first oral carbapenem for cUTI. The extended cash runway into 2028 also provides financial stability. However, the substantial decrease in revenue, the discontinuation of the SPR720 program, and the inherent regulatory and commercialization risks associated with drug development, coupled with reliance on GSK for commercialization, warrant a cautious "hold" recommendation. Investors should monitor the FDA approval process and commercial launch closely.

Keywords

Spero Therapeutics, SPRO, Tebipenem HBr, cUTI, complicated urinary tract infection, oral carbapenem, FDA submission, GSK, PIVOT-PO trial, Phase 3, biopharmaceutical, antibiotic, drug development, Q3 2025 results, SPR720, NTM-PD, clinical-stage, infectious diseases